The maintenance of an Overweight rating and a $65 price target by a reputable analyst firm like Cantor Fitzgerald suggests a positive outlook on Rocket Pharmaceuticals' stock. This endorsement could lead to increased investor confidence and potentially drive the stock price up in the short term.